HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Crinetics Pharmaceuticals (CRNX) and raises the price target from $42 to $50.
March 08, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Crinetics Pharmaceuticals and increases the price target from $42 to $50.
The upgrade in the price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong confidence in the company's future performance. This can lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100